Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ravulizumab · Ultomiris, ALXN-1210

Monoclonal antibody · Inhibitor of complement component C5 (C5) · developed by Alexion Pharm

Approved FDA, Dec 2018
AZN Developer
1 Registered trials

What is Ravulizumab?

Ravulizumab is an antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage into C5a and C5b and thereby preventing membrane attack complex formation. It is used in paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disorder and IgA nephropathy. It is also being studied in myasthenia gravis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ultomiris, ALXN-1210
Drug type
Monoclonal antibody
Targets
complement component C5 (C5)
Mechanism
Inhibitor of complement component C5 (C5)
Pathways
terminal complement activation, membrane attack complex (C5b-9) formation, C5a anaphylatoxin generation
Therapy area
Oncology
Developer
Alexion Pharm (AZN)
FDA status
Approved as Ultomiris (December 21, 2018), BLA761108 · FDA label
UNII
C3VX249T6L

✅ FDA-approved uses

From the indications section of the FDA label (version of Oct 29, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06909253 N/A Myasthenia Gravis, Generalized Recruiting AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Myasthenia Gravis, Generalized

Other drugs acting on C5

More from Alexion Pharm

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Ravulizumab

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.